Covered recipient · General Payments record
JAMES T PETERSON
Allopathic & Osteopathic Physicians Obstetrics & Gynecology Obstetrics
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$1,515.83
85 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,515.83 | 85 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $351.09 | 20 |
| Phathom Pharmaceuticals, Inc. | $216.59 | 6 |
| ViiV Healthcare Company | $156.79 | 9 |
| Lilly USA, LLC | $135.14 | 10 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $96.25 | 5 |
| Astellas Pharma US Inc | $60.56 | 3 |
| Gilead Sciences, Inc. | $52.22 | 2 |
| Amgen Inc. | $49.31 | 3 |
| GlaxoSmithKline, LLC. | $47.97 | 3 |
| PFIZER INC. | $46.88 | 5 |
| Merck Sharp & Dohme LLC | $45.15 | 3 |
| Dynavax Technologies Corporation | $40.53 | 3 |
| Otsuka America Pharmaceutical, Inc. | $30.92 | 2 |
| Corium, LLC | $25.71 | 1 |
| Alkermes, Inc. | $19.71 | 1 |
| Hologic Sales and Service, LLC | $18.71 | 1 |
| TREACE MEDICAL CONCEPTS, INC. | $18.59 | 1 |
| Exact Sciences Corporation | $17.58 | 1 |
| Corcept Therapeutics | $16.94 | 1 |
| IDORSIA PHARMACEUTICALS US INC | $15.94 | 1 |
| Supernus Pharmaceuticals, Inc. | $15.16 | 1 |
| Janssen Pharmaceuticals, Inc | $14.95 | 1 |
| Medtronic, Inc. | $13.13 | 1 |
| Organon Llc | $10.01 | 1 |
Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JAMES T PETERSON
NPI 1316962442 · CMS profile ID 331955
Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Obstetrics
SALT LAKE CITY, UT
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1316962442?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JAMES T PETERSON, NPI 1316962442, CMS profile ID 331955. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316962442?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). JAMES T PETERSON, NPI 1316962442, CMS profile ID 331955. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316962442?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- JAMES T PETERSON, NPI 1316962442, CMS profile ID 331955, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1316962442?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
85 matching records · $1,515.83 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–85 of 85.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | $15.80 | 04/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117352477 | CMS |
| IDORSIA PHARMACEUTICALS US INC | $15.94 | 04/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146776112 | CMS |
| ABBVIE INC. | $15.96 | 04/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105249449 | CMS |
| ViiV Healthcare Company | $20.41 | 04/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1112787734 | CMS |
| Merck Sharp & Dohme LLC | $14.76 | 04/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141982539 | CMS |
| Supernus Pharmaceuticals, Inc. | $15.16 | 04/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147900448 | CMS |
| ABBVIE INC. | $19.49 | 04/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105249445 | CMS |
| ABBVIE INC. | $10.65 | 03/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105249441 | CMS |
| ABBVIE INC. | $27.37 | 03/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105249437 | CMS |
| ViiV Healthcare Company | $24.71 | 03/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1112727747 | CMS |
| Lilly USA, LLC | $16.60 | 03/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135042298 | CMS |
| ABBVIE INC. | $18.94 | 03/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105249433 | CMS |
| Phathom Pharmaceuticals, Inc. | $9.75 | 03/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151110018 | CMS |
| ABBVIE INC. | $13.46 | 03/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105249425 | CMS |
| ABBVIE INC. | $25.95 | 03/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105249429 | CMS |
| PFIZER INC. | $7.62 | 03/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131807565 | CMS |
| ABBVIE INC. | $4.47 | 03/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105249416 | CMS |
| ABBVIE INC. | $34.54 | 03/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105249421 | CMS |
| Gilead Sciences, Inc. | $28.11 | 03/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133746414 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.90 | 03/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117962330 | CMS |
| Amgen Inc. | $16.55 | 03/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117352475 | CMS |
| ABBVIE INC. | $4.99 | 03/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105249413 | CMS |
| GlaxoSmithKline, LLC. | $13.96 | 03/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115766723 | CMS |
| Phathom Pharmaceuticals, Inc. | $7.47 | 02/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151110016 | CMS |
| Dynavax Technologies Corporation | $12.91 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1082143435 | CMS |
| Dynavax Technologies Corporation | $12.91 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1082145235 | CMS |
| ABBVIE INC. | $25.65 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105249405 | CMS |
| ABBVIE INC. | $1.22 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105249408 | CMS |
| Lilly USA, LLC | $14.67 | 02/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135048196 | CMS |
| Janssen Pharmaceuticals, Inc | $14.95 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078221171 | CMS |
| ViiV Healthcare Company | $17.12 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1112763458 | CMS |
| Otsuka America Pharmaceutical, Inc. | $13.25 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118960629 | CMS |
| ABBVIE INC. | $20.25 | 01/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105249401 | CMS |
| Lilly USA, LLC | $13.70 | 01/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135023860 | CMS |
| ABBVIE INC. | $14.91 | 01/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105249397 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,439,541.56 | 358 |
| PY2024 | Recipient | $6,258.51 | 12 |
| PY2024 | Principal investigator | $2,839,707.80 | 547 |
| PY2023 | Recipient | $3,920.00 | 4 |
| PY2023 | Principal investigator | $3,094,774.97 | 228 |
| PY2022 | Recipient | $4,600.00 | 2 |
| PY2022 | Principal investigator | $3,020,277.43 | 422 |
| PY2021 | Recipient | $7,670.00 | 4 |
| PY2021 | Principal investigator | $4,728,078.37 | 431 |
| PY2020 | Recipient | $8,210.00 | 4 |
| PY2020 | Principal investigator | $2,099,134.68 | 174 |
| PY2019 | Principal investigator | $2,146,118.67 | 271 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
358 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $250.00 | 12/31/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension | No dispute reported | 06/30/2026 | 1202534451 |
| Principal investigator 1 | PFIZER INC. | $15,746.40 | 12/31/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 | No dispute reported | 06/30/2026 | 1228719769 |
| Principal investigator 1 | PFIZER INC. | $6,562.20 | 12/31/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228735703 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 12/23/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291228 |
| Principal investigator 1 | Ipsen Innovation | $1,182.33 | 12/23/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291230 |
| Principal investigator 1 | PFIZER INC. | $4,050.00 | 12/23/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228746887 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,000.00 | 12/19/2025 | Non-covered Recipient Entity J Lewis Research,incorporation | A Phase 3 Randomized, Modified Double-blind, Active-controlled Study to Assess the Safety of vYF, Yellow Fever Vaccine, in Adults Aged 18 Years up to 60 Years | No dispute reported | 06/30/2026 | 1226099600 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $935.55 | 12/19/2025 | Non-covered Recipient Entity J Lewis Research,incorporation | A Phase 3 Randomized, Modified Double-blind, Active-controlled Study to Assess the Safety of vYF, Yellow Fever Vaccine, in Adults Aged 18 Years up to 60 Years | No dispute reported | 06/30/2026 | 1226099606 |
| Principal investigator 1 | PFIZER INC. | $52,772.06 | 12/17/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228707323 |
| Principal investigator 1 | PFIZER INC. | $23,287.50 | 12/17/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228747013 |
| Principal investigator 1 | Ipsen Innovation | $200.00 | 12/15/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291226 |
| Principal investigator 1 | PFIZER INC. | $587.50 | 12/15/2025 | Non-covered Recipient Entity J Lewis Research IncFoothill Family Clinic | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228718421 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 12/12/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184294605 |
| Principal investigator 1 | Ipsen Innovation | $180.00 | 12/11/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184294603 |
| Principal investigator 1 | PFIZER INC. | $1,219.40 | 12/10/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228726006 |
| Principal investigator 1 | PFIZER INC. | $61,784.90 | 12/09/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 | No dispute reported | 06/30/2026 | 1228751143 |
| Principal investigator 1 | PFIZER INC. | $757.50 | 12/08/2025 | Non-covered Recipient Entity Foothill Family Clinic J Lewis Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228723904 |
| Principal investigator 1 | PFIZER INC. | $1,170.00 | 12/08/2025 | Non-covered Recipient Entity Foothill Family Clinic J Lewis Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228727829 |
| Principal investigator 1 | ModernaTX, Inc. | $250.00 | 12/05/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963653 |
| Principal investigator 1 | ModernaTX, Inc. | $4,605.46 | 12/05/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963681 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 12/05/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963723 |
| Principal investigator 1 | ABBVIE INC. | $15,000.00 | 12/04/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202528314 |
| Principal investigator 1 | ModernaTX, Inc. | $15,312.38 | 12/01/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963737 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 11/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291216 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 11/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291218 |
| Principal investigator 1 | Ipsen Innovation | $2,567.16 | 11/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291220 |
| Principal investigator 1 | Ipsen Innovation | $1,182.33 | 11/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291222 |
| Principal investigator 1 | Ipsen Innovation | $3,112.49 | 11/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291224 |
| Principal investigator 1 | PFIZER INC. | $27,337.50 | 11/27/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228730476 |
| Principal investigator 1 | PFIZER INC. | $15,300.00 | 11/27/2025 | Non-covered Recipient Entity JLewis Research Inc | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228737588 |
| Principal investigator 1 | PFIZER INC. | $9,231.57 | 11/26/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228707247 |
| Principal investigator 1 | PFIZER INC. | $29,681.50 | 11/26/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228726824 |
| Principal investigator 1 | PFIZER INC. | $4,168.00 | 11/26/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228728321 |
| Principal investigator 1 | PFIZER INC. | $4,050.00 | 11/20/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228738694 |
| Principal investigator 1 | PFIZER INC. | $1,400.00 | 11/19/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228730140 |
| Principal investigator 1 | PFIZER INC. | $6,711.45 | 11/18/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228720771 |
| Principal investigator 1 | PFIZER INC. | $175.50 | 11/14/2025 | Non-covered Recipient Entity J Lewis Res Foothill Clnc | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 | No dispute reported | 06/30/2026 | 1228723906 |
| Principal investigator 1 | PFIZER INC. | $222.90 | 11/14/2025 | Non-covered Recipient Entity J Lewis Res Foothill Clnc | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 | No dispute reported | 06/30/2026 | 1228728357 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $6,420.89 | 11/14/2025 | Non-covered Recipient Entity J Lewis Research,incorporation | A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | No dispute reported | 06/30/2026 | 1226099563 |
| Principal investigator 1 | PFIZER INC. | $35,227.08 | 11/13/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228707245 |
| Principal investigator 1 | PFIZER INC. | $272.70 | 11/12/2025 | Non-covered Recipient Entity J Lewis Research Inc North | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228722580 |
| Principal investigator 1 | PFIZER INC. | $221.58 | 11/12/2025 | Non-covered Recipient Entity J Lewis Research Inc North | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228729669 |
| Principal investigator 1 | PFIZER INC. | $16,752.70 | 11/11/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228724434 |
| Principal investigator 1 | ModernaTX, Inc. | $998.40 | 11/07/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963649 |
| Principal investigator 1 | ModernaTX, Inc. | $501.80 | 11/07/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963715 |
| Principal investigator 1 | PFIZER INC. | $95,616.36 | 11/05/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228707325 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $919.58 | 10/31/2025 | Non-covered Recipient Entity J Lewis Research,inc | Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults | No dispute reported | 06/30/2026 | 1226100354 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $919.58 | 10/31/2025 | Non-covered Recipient Entity J Lewis Research,inc | Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults | No dispute reported | 06/30/2026 | 1226100359 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $919.58 | 10/31/2025 | Non-covered Recipient Entity J Lewis Research,inc | Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults | No dispute reported | 06/30/2026 | 1226100363 |
| Principal investigator 1 | Ipsen Innovation | $29.16 | 10/30/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291188 |
| Principal investigator 1 | Ipsen Innovation | $101.25 | 10/30/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291198 |
| Principal investigator 1 | Ipsen Innovation | $29.16 | 10/30/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291200 |
| Principal investigator 1 | Ipsen Innovation | $101.25 | 10/30/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291204 |
| Principal investigator 1 | Ipsen Innovation | $101.25 | 10/30/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291208 |
| Principal investigator 1 | PFIZER INC. | $148.60 | 10/30/2025 | Non-covered Recipient Entity J Lewis Res Foothill Clnc | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 | No dispute reported | 06/30/2026 | 1228723912 |
| Principal investigator 1 | PFIZER INC. | $117.00 | 10/30/2025 | Non-covered Recipient Entity J Lewis Res Foothill Clnc | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 | No dispute reported | 06/30/2026 | 1228729191 |
| Principal investigator 1 | ModernaTX, Inc. | $400.00 | 10/29/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963677 |
| Principal investigator 1 | Ipsen Innovation | $2,153.79 | 10/27/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291186 |
| Principal investigator 1 | Ipsen Innovation | $2,567.16 | 10/27/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291190 |
| Principal investigator 1 | Ipsen Innovation | $101.25 | 10/27/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291192 |
| Principal investigator 1 | Ipsen Innovation | $2,567.16 | 10/27/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291194 |
| Principal investigator 1 | Ipsen Innovation | $101.25 | 10/27/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291196 |
| Principal investigator 1 | Ipsen Innovation | $3,112.49 | 10/27/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291202 |
| Principal investigator 1 | Ipsen Innovation | $2,458.35 | 10/27/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291206 |
| Principal investigator 1 | Ipsen Innovation | $3,112.49 | 10/27/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291210 |
| Principal investigator 1 | Ipsen Innovation | $101.25 | 10/27/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291212 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 10/27/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291214 |
| Principal investigator 1 | PFIZER INC. | $148.60 | 10/27/2025 | Non-covered Recipient Entity J Lewis Res Foothill Clnc | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 | No dispute reported | 06/30/2026 | 1228723910 |
| Principal investigator 1 | PFIZER INC. | $117.00 | 10/27/2025 | Non-covered Recipient Entity J Lewis Res Foothill Clnc | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 | No dispute reported | 06/30/2026 | 1228727827 |
| Principal investigator 1 | PFIZER INC. | $88,011.70 | 10/25/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228743332 |
| Principal investigator 1 | Ipsen Innovation | $90.00 | 10/23/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184294601 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $8,139.58 | 10/23/2025 | Non-covered Recipient Entity J Lewis Research,incorporation | A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | No dispute reported | 06/30/2026 | 1226099570 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $5,209.66 | 10/23/2025 | Non-covered Recipient Entity J Lewis Research,incorporation | A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | No dispute reported | 06/30/2026 | 1226099576 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $486.00 | 10/23/2025 | Non-covered Recipient Entity J Lewis Research,incorporation | A Phase 3 Randomized, Modified Double-blind, Active-controlled Study to Assess the Safety of vYF, Yellow Fever Vaccine, in Adults Aged 18 Years up to 60 Years | No dispute reported | 06/30/2026 | 1226099582 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,026.70 | 10/23/2025 | Non-covered Recipient Entity J Lewis Research,incorporation | A Phase 3 Randomized, Modified Double-blind, Active-controlled Study to Assess the Safety of vYF, Yellow Fever Vaccine, in Adults Aged 18 Years up to 60 Years | No dispute reported | 06/30/2026 | 1226099588 |
| Principal investigator 1 | ModernaTX, Inc. | $14,628.60 | 10/22/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963741 |
| Principal investigator 1 | PFIZER INC. | $287.00 | 10/22/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228718755 |
| Principal investigator 1 | PFIZER INC. | $272.70 | 10/17/2025 | Non-covered Recipient Entity JLewisFoothill Family Clinic | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228706979 |
| Principal investigator 1 | PFIZER INC. | $172.34 | 10/17/2025 | Non-covered Recipient Entity JLewisFoothill Family Clinic | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228707149 |
| Principal investigator 1 | PFIZER INC. | $12.31 | 10/17/2025 | Non-covered Recipient Entity JLewisFoothill Family Clinic | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228707151 |
| Principal investigator 1 | PFIZER INC. | $39,487.50 | 10/11/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228742323 |
| Principal investigator 1 | ModernaTX, Inc. | $4,800.00 | 10/03/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963739 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $30,196.65 | 10/03/2025 | Non-covered Recipient Entity J Lewis Research,incorporation | A Phase 3 Randomized, Modified Double-blind, Active-controlled Study to Assess the Safety of vYF, Yellow Fever Vaccine, in Adults Aged 18 Years up to 60 Years | No dispute reported | 06/30/2026 | 1226099557 |
| Principal investigator 1 | ModernaTX, Inc. | $11,511.06 | 10/01/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963699 |
| Principal investigator 1 | PFIZER INC. | $861.00 | 10/01/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228718417 |
| Principal investigator 1 | Ipsen Innovation | $90.00 | 09/29/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184294591 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 09/29/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184294593 |
| Principal investigator 1 | PFIZER INC. | $530.25 | 09/29/2025 | Non-covered Recipient Entity JLewisFoothill Family Clinic | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228739573 |
| Principal investigator 1 | PFIZER INC. | $430.85 | 09/29/2025 | Non-covered Recipient Entity JLewisFoothill Family Clinic | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228739634 |
| Principal investigator 1 | PFIZER INC. | $22,975.00 | 09/27/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228762498 |
| Principal investigator 1 | PFIZER INC. | $1,722.00 | 09/24/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228718419 |
| Principal investigator 1 | PFIZER INC. | $615.50 | 09/24/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228719933 |
| Principal investigator 1 | PFIZER INC. | $660.50 | 09/24/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228748149 |
| Principal investigator 1 | PFIZER INC. | $14,175.00 | 09/24/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228758717 |
| Principal investigator 1 | ModernaTX, Inc. | $7,925.18 | 09/19/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963663 |
| Principal investigator 1 | ModernaTX, Inc. | $360.00 | 09/17/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963667 |
| Principal investigator 1 | PFIZER INC. | $2,602.80 | 09/17/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228759101 |
| Principal investigator 1 | PFIZER INC. | $2,392.62 | 09/10/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228768845 |
| Principal investigator 1 | PFIZER INC. | $17,212.50 | 09/09/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228758899 |
| Principal investigator 1 | ModernaTX, Inc. | $250.00 | 09/03/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963727 |
| Principal investigator 1 | Ipsen Innovation | $180.00 | 09/02/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184294595 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 09/02/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184294597 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 09/02/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184294599 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 08/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291168 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 08/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291182 |
| Principal investigator 1 | ModernaTX, Inc. | $59.28 | 08/28/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004745 |
| Principal investigator 1 | ModernaTX, Inc. | $240.00 | 08/27/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963685 |
| Principal investigator 1 | ModernaTX, Inc. | $12,054.90 | 08/27/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963701 |
| Principal investigator 1 | ModernaTX, Inc. | $1,667.25 | 08/27/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963703 |
| Principal investigator 1 | PFIZER INC. | $10,551.80 | 08/27/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228785177 |
| Principal investigator 1 | Ipsen Innovation | $2,539.55 | 08/25/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291150 |
| Principal investigator 1 | Ipsen Innovation | $3,047.69 | 08/25/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291152 |
| Principal investigator 1 | Ipsen Innovation | $3,047.69 | 08/25/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291156 |
| Principal investigator 1 | Ipsen Innovation | $2,237.69 | 08/25/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291158 |
| Principal investigator 1 | Ipsen Innovation | $3,047.69 | 08/25/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291160 |
| Principal investigator 1 | Ipsen Innovation | $3,047.69 | 08/25/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291162 |
| Principal investigator 1 | Ipsen Innovation | $3,047.69 | 08/25/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291164 |
| Principal investigator 1 | Ipsen Innovation | $3,047.69 | 08/25/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291166 |
| Principal investigator 1 | Ipsen Innovation | $3,047.69 | 08/25/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291170 |
| Principal investigator 1 | Ipsen Innovation | $3,047.69 | 08/25/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291172 |
| Principal investigator 1 | Ipsen Innovation | $2,382.41 | 08/25/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291174 |
| Principal investigator 1 | Ipsen Innovation | $2,445.59 | 08/25/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291176 |
| Principal investigator 1 | Ipsen Innovation | $5,338.03 | 08/25/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291180 |
| Principal investigator 1 | Ipsen Innovation | $3,047.73 | 08/25/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291184 |
| Principal investigator 1 | ModernaTX, Inc. | $7,321.73 | 08/22/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963733 |
| Principal investigator 1 | Ipsen Innovation | $3,047.69 | 08/14/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291154 |
| Principal investigator 1 | Ipsen Innovation | $3,047.70 | 08/14/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291178 |
| Principal investigator 1 | PFIZER INC. | $9,791.55 | 08/14/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228761660 |
| Principal investigator 1 | PFIZER INC. | $88,548.75 | 08/09/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228786325 |
| Principal investigator 1 | ModernaTX, Inc. | $160.00 | 08/06/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963745 |
| Principal investigator 1 | PFIZER INC. | $5,062.50 | 08/05/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228786166 |
| Principal investigator 1 | PFIZER INC. | $14,134.00 | 08/02/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228789455 |
| Principal investigator 1 | PFIZER INC. | $49,912.50 | 08/01/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228719707 |
| Principal investigator 1 | PFIZER INC. | $10,759.20 | 07/31/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228765109 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 07/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291142 |
| Principal investigator 1 | Ipsen Innovation | $2,153.79 | 07/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291146 |
| Principal investigator 1 | Ipsen Innovation | $1,848.15 | 07/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291148 |
| Principal investigator 1 | PFIZER INC. | $4,875.96 | 07/26/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228724214 |
| Principal investigator 1 | Ipsen Innovation | $300.00 | 07/25/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184294585 |
| Principal investigator 1 | ModernaTX, Inc. | $26,938.58 | 07/25/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963669 |
| Principal investigator 1 | Ipsen Innovation | $221.33 | 07/17/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291144 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 07/17/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184294587 |
| Principal investigator 1 | Ipsen Innovation | $300.00 | 07/17/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184294589 |
| Principal investigator 1 | ModernaTX, Inc. | $240.00 | 07/16/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963729 |
| Principal investigator 1 | ModernaTX, Inc. | $624.00 | 07/14/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004737 |
| Principal investigator 1 | PFIZER INC. | $13,449.00 | 07/11/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228764297 |
| Principal investigator 1 | PFIZER INC. | $20,250.00 | 07/11/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228782098 |
| Principal investigator 1 | PFIZER INC. | $123.10 | 07/10/2025 | Non-covered Recipient Entity JLewisFoothill Family Clinic | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228739630 |
| Principal investigator 1 | PFIZER INC. | $151.50 | 07/10/2025 | Non-covered Recipient Entity JLewisFoothill Family Clinic | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228748047 |
| Principal investigator 1 | PFIZER INC. | $98,872.03 | 07/08/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228781928 |
| Principal investigator 1 | ModernaTX, Inc. | $2,926.20 | 07/02/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963717 |
| Principal investigator 1 | ModernaTX, Inc. | $350.00 | 07/02/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963725 |
| Principal investigator 1 | PFIZER INC. | $1,365.19 | 07/01/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228762986 |
| Principal investigator 1 | Ipsen Innovation | $2,153.79 | 06/30/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291112 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 06/30/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291114 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 06/30/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291116 |
| Principal investigator 1 | Ipsen Innovation | $2,005.56 | 06/30/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291118 |
| Principal investigator 1 | Ipsen Innovation | $2,005.56 | 06/30/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291120 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 06/30/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291124 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 06/30/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291126 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 06/30/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291128 |
| Principal investigator 1 | Ipsen Innovation | $101.25 | 06/30/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291130 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 06/30/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291132 |
| Principal investigator 1 | Ipsen Innovation | $2,153.79 | 06/30/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291134 |
| Principal investigator 1 | Ipsen Innovation | $1,182.33 | 06/30/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291138 |
| Principal investigator 1 | Ipsen Innovation | $2,567.16 | 06/30/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291140 |
| Principal investigator 1 | PFIZER INC. | $5,028.30 | 06/27/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228778159 |
| Principal investigator 1 | Ipsen Innovation | $100.00 | 06/26/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291122 |
| Principal investigator 1 | PFIZER INC. | $896.60 | 06/26/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228774166 |
| Principal investigator 1 | PFIZER INC. | $18,146.70 | 06/26/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228777518 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,500.00 | 06/25/2025 | Non-covered Recipient Entity J Lewis Research,inc | Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults | No dispute reported | 06/30/2026 | 1226100335 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $750.00 | 06/25/2025 | Non-covered Recipient Entity J Lewis Research,inc | Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults | No dispute reported | 06/30/2026 | 1226100340 |
| Principal investigator 1 | Ipsen Innovation | $16.94 | 06/23/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291136 |
| Principal investigator 1 | PFIZER INC. | $10,031.85 | 06/21/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228777828 |
| Principal investigator 1 | ModernaTX, Inc. | $13,694.40 | 06/18/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963665 |
| Principal investigator 1 | ModernaTX, Inc. | $448.30 | 06/18/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004735 |
| Principal investigator 1 | PFIZER INC. | $2,373.30 | 06/14/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228778300 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,604.83 | 06/12/2025 | Non-covered Recipient Entity J Lewis Research,incorporation | A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | No dispute reported | 06/30/2026 | 1226099594 |
| Principal investigator 1 | PFIZER INC. | $96,346.18 | 06/10/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228778625 |
| Principal investigator 1 | ModernaTX, Inc. | $4,466.44 | 06/04/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963679 |
| Principal investigator 1 | ModernaTX, Inc. | $324.00 | 06/02/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963651 |
| Principal investigator 1 | ModernaTX, Inc. | $162.00 | 06/02/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963721 |
| Principal investigator 1 | PFIZER INC. | $12,465.90 | 05/30/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228771553 |
| Principal investigator 1 | Ipsen Innovation | $400.00 | 05/29/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291110 |
| Principal investigator 1 | Ipsen Innovation | $200.00 | 05/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291108 |
| Principal investigator 1 | ModernaTX, Inc. | $80.00 | 05/28/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963691 |
| Principal investigator 1 | ModernaTX, Inc. | $46,623.20 | 05/28/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004741 |
| Principal investigator 1 | ModernaTX, Inc. | $9,321.78 | 05/28/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004751 |
| Principal investigator 1 | ModernaTX, Inc. | $12,330.24 | 05/28/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004753 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $919.58 | 05/28/2025 | Non-covered Recipient Entity J Lewis Research,inc | Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults | No dispute reported | 06/30/2026 | 1226100347 |
| Principal investigator 1 | PFIZER INC. | $1,016.54 | 05/27/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707864 |
| Principal investigator 1 | PFIZER INC. | $1,016.54 | 05/27/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228761487 |
| Principal investigator 1 | PFIZER INC. | $378.70 | 05/23/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228762798 |
| Principal investigator 1 | ModernaTX, Inc. | $28,382.26 | 05/21/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963659 |
| Principal investigator 1 | PFIZER INC. | $72.61 | 05/21/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228706745 |
| Principal investigator 1 | PFIZER INC. | $18.98 | 05/21/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228706747 |
| Principal investigator 1 | PFIZER INC. | $72.61 | 05/21/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228762076 |
| Principal investigator 1 | PFIZER INC. | $18.98 | 05/21/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228770610 |
| Principal investigator 1 | PFIZER INC. | $3,600.00 | 05/21/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228783071 |
| Principal investigator 1 | ModernaTX, Inc. | $229.50 | 05/16/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963671 |
| Principal investigator 1 | ModernaTX, Inc. | $300.00 | 05/16/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963695 |
| Principal investigator 1 | PFIZER INC. | $45,121.06 | 05/15/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228762901 |
| Principal investigator 1 | PFIZER INC. | $2,700.00 | 05/08/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228782813 |
| Principal investigator 1 | PFIZER INC. | $492.00 | 05/07/2025 | Non-covered Recipient Entity JLewis Foothill Family Clin S | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228768635 |
| Principal investigator 1 | PFIZER INC. | $564.40 | 05/07/2025 | Non-covered Recipient Entity JLewis Foothill Family Clin S | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228771136 |
| Principal investigator 1 | ModernaTX, Inc. | $3,235.32 | 05/02/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963655 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $12,000.00 | 05/02/2025 | Non-covered Recipient Entity J Lewis Research,incorporation | A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | No dispute reported | 06/30/2026 | 1226099542 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,500.00 | 05/02/2025 | Non-covered Recipient Entity J Lewis Research,incorporation | A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | No dispute reported | 06/30/2026 | 1226099547 |
| Principal investigator 1 | PFIZER INC. | $28,979.18 | 05/01/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228764731 |
| Principal investigator 1 | Ipsen Innovation | $3,112.36 | 04/30/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291084 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $919.58 | 04/30/2025 | Non-covered Recipient Entity J Lewis Research,inc | Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults | No dispute reported | 06/30/2026 | 1226100321 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $919.58 | 04/30/2025 | Non-covered Recipient Entity J Lewis Research,inc | Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults | No dispute reported | 06/30/2026 | 1226100328 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291054 |
| Principal investigator 1 | Ipsen Innovation | $101.25 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291056 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291058 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291060 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291064 |
| Principal investigator 1 | Ipsen Innovation | $2,153.79 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291066 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291068 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291078 |
| Principal investigator 1 | Ipsen Innovation | $2,005.56 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291080 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291082 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291088 |
| Principal investigator 1 | Ipsen Innovation | $2,005.56 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291090 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291092 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291094 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291096 |
| Principal investigator 1 | Ipsen Innovation | $2,153.79 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291098 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291100 |
| Principal investigator 1 | Ipsen Innovation | $2,458.35 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291102 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291104 |
| Principal investigator 1 | Ipsen Innovation | $2,153.79 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291106 |
| Principal investigator 1 | ModernaTX, Inc. | $34,967.40 | 04/28/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004749 |
| Principal investigator 1 | ModernaTX, Inc. | $15,536.30 | 04/28/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004767 |
| Principal investigator 1 | ModernaTX, Inc. | $18,179.20 | 04/28/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004769 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,604.83 | 04/28/2025 | Non-covered Recipient Entity J Lewis Research,incorporation | A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | No dispute reported | 06/30/2026 | 1226099552 |
| Principal investigator 1 | PFIZER INC. | $595.82 | 04/25/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228722864 |
| Principal investigator 1 | PFIZER INC. | $896.60 | 04/24/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228796714 |
| Principal investigator 1 | Ipsen Innovation | $600.00 | 04/23/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291074 |
| Principal investigator 1 | Ipsen Innovation | $180.00 | 04/23/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291076 |
| Principal investigator 1 | ModernaTX, Inc. | $11,160.45 | 04/18/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963689 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 04/16/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291070 |
| Principal investigator 1 | Ipsen Innovation | $270.00 | 04/16/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291072 |
| Principal investigator 1 | PFIZER INC. | $6,019.82 | 04/16/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228794594 |
| Principal investigator 1 | Ipsen Innovation | $500.00 | 04/14/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291062 |
| Principal investigator 1 | PFIZER INC. | $6,921.04 | 04/10/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228779993 |
| Principal investigator 1 | PFIZER INC. | $143.10 | 04/09/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228791695 |
| Principal investigator 1 | PFIZER INC. | $7,172.80 | 04/08/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228724638 |
| Principal investigator 1 | ModernaTX, Inc. | $654.75 | 04/04/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963683 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 04/02/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963707 |
| Principal investigator 1 | ModernaTX, Inc. | $10,831.51 | 04/02/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963719 |
| Principal investigator 1 | Ipsen Innovation | $350.00 | 04/01/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291086 |
| Principal investigator 1 | Ipsen Innovation | $90.00 | 03/31/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291052 |
| Principal investigator 1 | PFIZER INC. | $28,610.27 | 03/28/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228797815 |
| Principal investigator 1 | PFIZER INC. | $823.50 | 03/26/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228779695 |
| Principal investigator 1 | ModernaTX, Inc. | $1,965.60 | 03/24/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004739 |
| Principal investigator 1 | ModernaTX, Inc. | $1,344.90 | 03/24/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004743 |
| Principal investigator 1 | ModernaTX, Inc. | $2,545.14 | 03/24/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004755 |
| Principal investigator 1 | ModernaTX, Inc. | $21,750.82 | 03/24/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004761 |
| Principal investigator 1 | ModernaTX, Inc. | $187.20 | 03/24/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004773 |
| Principal investigator 1 | ModernaTX, Inc. | $16,183.44 | 03/24/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004775 |
| Principal investigator 1 | PFIZER INC. | $189.80 | 03/24/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707862 |
| Principal investigator 1 | PFIZER INC. | $189.80 | 03/23/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228769711 |
| Principal investigator 1 | PFIZER INC. | $4,480.08 | 03/22/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228787498 |
| Principal investigator 1 | PFIZER INC. | $4,168.00 | 03/22/2025 | Non-covered Recipient Entity J Lewis Research Inc | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228788993 |
| Principal investigator 1 | PFIZER INC. | $24,776.55 | 03/22/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228795460 |
| Principal investigator 1 | ModernaTX, Inc. | $7,670.02 | 03/21/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963661 |
| Principal investigator 1 | ModernaTX, Inc. | $240.00 | 03/21/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963735 |
| Principal investigator 1 | PFIZER INC. | $92,896.30 | 03/20/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228795420 |
| Principal investigator 1 | ModernaTX, Inc. | $200.00 | 03/14/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963675 |
| Principal investigator 1 | ModernaTX, Inc. | $200.00 | 03/14/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963697 |
| Principal investigator 1 | Ipsen Innovation | $506.25 | 03/10/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291002 |
| Principal investigator 1 | Ipsen Innovation | $405.00 | 03/10/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291004 |
| Principal investigator 1 | Ipsen Innovation | $750.00 | 03/10/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291006 |
| Principal investigator 1 | Ipsen Innovation | $47.79 | 03/10/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291008 |
| Principal investigator 1 | Ipsen Innovation | $47.79 | 03/10/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291010 |
| Principal investigator 1 | Ipsen Innovation | $47.79 | 03/10/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291014 |
| Principal investigator 1 | Ipsen Innovation | $303.75 | 03/10/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291016 |
| Principal investigator 1 | Ipsen Innovation | $47.79 | 03/10/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291018 |
| Principal investigator 1 | Ipsen Innovation | $47.79 | 03/10/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291020 |
| Principal investigator 1 | Ipsen Innovation | $607.50 | 03/10/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291022 |
| Principal investigator 1 | Ipsen Innovation | $202.50 | 03/10/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291024 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 03/10/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291026 |
| Principal investigator 1 | Ipsen Innovation | $202.50 | 03/10/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291028 |
| Principal investigator 1 | Ipsen Innovation | $47.79 | 03/10/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291030 |
| Principal investigator 1 | Ipsen Innovation | $202.50 | 03/10/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291032 |
| Principal investigator 1 | Ipsen Innovation | $47.79 | 03/10/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291034 |
| Principal investigator 1 | Ipsen Innovation | $202.50 | 03/10/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291042 |
| Principal investigator 1 | PFIZER INC. | $189.80 | 03/10/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228706743 |
| Principal investigator 1 | PFIZER INC. | $189.80 | 03/10/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228770848 |
| Principal investigator 1 | Ipsen Innovation | $3,047.71 | 03/06/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291012 |
| Principal investigator 1 | Ipsen Innovation | $2,300.60 | 03/06/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291036 |
| Principal investigator 1 | Ipsen Innovation | $3,047.69 | 03/06/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291038 |
| Principal investigator 1 | Ipsen Innovation | $2,291.96 | 03/06/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291040 |
| Principal investigator 1 | Ipsen Innovation | $3,047.69 | 03/06/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291044 |
| Principal investigator 1 | Ipsen Innovation | $3,047.69 | 03/06/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291046 |
| Principal investigator 1 | Ipsen Innovation | $3,047.69 | 03/06/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291048 |
| Principal investigator 1 | Ipsen Innovation | $3,047.69 | 03/06/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291050 |
| Principal investigator 1 | PFIZER INC. | $6,276.20 | 03/04/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228789497 |
| Principal investigator 1 | PFIZER INC. | $14,600.00 | 03/04/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228789631 |
| Principal investigator 1 | ModernaTX, Inc. | $27,794.60 | 02/27/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004759 |
| Principal investigator 1 | ModernaTX, Inc. | $18,218.72 | 02/27/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004763 |
| Principal investigator 1 | ModernaTX, Inc. | $20,197.19 | 02/27/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004777 |
| Principal investigator 1 | ModernaTX, Inc. | $19,821.38 | 02/26/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963705 |
| Principal investigator 1 | PFIZER INC. | $13,449.00 | 02/26/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228748889 |
| Principal investigator 1 | PFIZER INC. | $6,447.19 | 02/26/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228762516 |
| Principal investigator 1 | PFIZER INC. | $69,405.07 | 02/25/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228757096 |
| Principal investigator 1 | ModernaTX, Inc. | $93.60 | 02/20/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004733 |
| Principal investigator 1 | PFIZER INC. | $487.35 | 02/19/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228759306 |
| Principal investigator 1 | PFIZER INC. | $5,746.68 | 02/19/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228761323 |
| Principal investigator 1 | PFIZER INC. | $472.50 | 02/14/2025 | Non-covered Recipient Entity J Lewis Research Inc | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228752166 |
| Principal investigator 1 | ModernaTX, Inc. | $25,118.24 | 02/12/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252963693 |
| Principal investigator 1 | ModernaTX, Inc. | $160.00 | 02/12/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963743 |
| Principal investigator 1 | PFIZER INC. | $28,633.50 | 02/12/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228757879 |
| Principal investigator 1 | PFIZER INC. | $376.85 | 02/08/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228743646 |
| Principal investigator 1 | PFIZER INC. | $2,350.00 | 02/04/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707940 |
| Principal investigator 1 | ModernaTX, Inc. | $976.05 | 02/03/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252963709 |
| Principal investigator 1 | ModernaTX, Inc. | $361.05 | 02/03/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252963711 |
| Principal investigator 1 | ModernaTX, Inc. | $11,594.35 | 02/03/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252963713 |
| Principal investigator 1 | PFIZER INC. | $726.10 | 02/03/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707936 |
| Principal investigator 1 | PFIZER INC. | $317.00 | 02/03/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707938 |
| Principal investigator 1 | PFIZER INC. | $317.00 | 02/03/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228769715 |
| Principal investigator 1 | PFIZER INC. | $726.10 | 02/03/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228770605 |
| Principal investigator 1 | PFIZER INC. | $837.08 | 02/03/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228785091 |
| Principal investigator 1 | PFIZER INC. | $981.24 | 02/03/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228786743 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $5,000.00 | 02/01/2025 | Non-covered Recipient Entity J Lewis Research,incorporation | Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years. | No dispute reported | 06/30/2026 | 1226099526 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,000.00 | 02/01/2025 | Non-covered Recipient Entity J Lewis Research,incorporation | Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years. | No dispute reported | 06/30/2026 | 1226099532 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $8,405.21 | 02/01/2025 | Non-covered Recipient Entity J Lewis Research,incorporation | Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years. | No dispute reported | 06/30/2026 | 1226099537 |
| Principal investigator 1 | ModernaTX, Inc. | $13,104.00 | 01/30/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004757 |
| Principal investigator 1 | Ipsen Innovation | $200.00 | 01/29/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184290998 |
| Principal investigator 1 | ModernaTX, Inc. | $748.80 | 01/29/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine | No dispute reported | 06/30/2026 | 1252963657 |
| Principal investigator 1 | PFIZER INC. | $478.71 | 01/29/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228801240 |
| Principal investigator 1 | PFIZER INC. | $11,199.97 | 01/28/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228800258 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 01/27/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184290982 |
| Principal investigator 1 | Ipsen Innovation | $956.34 | 01/27/2025 | Non-covered Recipient Entity J Lewis Research, Inc | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184291000 |
| Principal investigator 1 | ModernaTX, Inc. | $11,539.84 | 01/27/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004747 |
| Principal investigator 1 | ModernaTX, Inc. | $27,965.34 | 01/27/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004765 |
| Principal investigator 1 | ModernaTX, Inc. | $17,932.00 | 01/27/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253004771 |
| Principal investigator 1 | PFIZER INC. | $22,513.10 | 01/25/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228801660 |
| Principal investigator 1 | ModernaTX, Inc. | $125.00 | 01/24/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963687 |
| Principal investigator 1 | ModernaTX, Inc. | $28,782.67 | 01/24/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963731 |
| Principal investigator 1 | Ipsen Innovation | $100.00 | 01/23/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184290996 |
| Principal investigator 1 | PFIZER INC. | $5,165.63 | 01/22/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228798741 |
| Principal investigator 1 | PFIZER INC. | $1,436.13 | 01/22/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228798771 |
| Principal investigator 1 | Ipsen Innovation | $47.79 | 01/20/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184290984 |
| Principal investigator 1 | Ipsen Innovation | $101.25 | 01/20/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184290986 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 01/20/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184290988 |
| Principal investigator 1 | Ipsen Innovation | $101.25 | 01/20/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184290992 |
| Principal investigator 1 | Ipsen Innovation | $47.79 | 01/20/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184290994 |
| Principal investigator 1 | PFIZER INC. | $2,562.70 | 01/15/2025 | Non-covered Recipient Entity J Lewis Research Inc | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228720071 |
| Principal investigator 1 | PFIZER INC. | $1,436.13 | 01/15/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228801667 |
| Principal investigator 1 | PFIZER INC. | $1,435.00 | 01/13/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228770601 |
| Principal investigator 1 | PFIZER INC. | $13,199.12 | 01/09/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228800862 |
| Principal investigator 1 | Ipsen Innovation | $180.00 | 01/08/2025 | Non-covered Recipient Entity J Lewis Research, Inc | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184290990 |
| Principal investigator 1 | PFIZER INC. | $478.71 | 01/08/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228800238 |
| Principal investigator 1 | PFIZER INC. | $1,435.00 | 01/06/2025 | Non-covered Recipient Entity J Lewis Research Inc Foothill Family Clinic | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228707860 |
| Principal investigator 1 | ModernaTX, Inc. | $160.00 | 01/03/2025 | Non-covered Recipient Entity J LEWIS RESEARCH INC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252963673 |
| Principal investigator 1 | PFIZER INC. | $478.71 | 01/01/2025 | Non-covered Recipient Entity J Lewis Research Inc | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228799409 |